RxDoctor Payments Data

Shireen Rostami, PA

Physician Assistant · Dallas, TXNPI 1730750605

Payments from drug & device makers

$1,610in general payments, 2019–2025

Across 109 payments — averaging $14.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$650
  • Sumitomo Pharma America, Inc.$331
  • Urovant Sciences Inc$268
  • Astellas Pharma US Inc$205
  • Convatec Inc.$59
  • Vertex$23
  • plus $74 from 4 others

What the payments were for

  • Food & beverage$1,42488%
  • Education$18512%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)32$650
Sumitomo Pharma America, Inc.43$331
Urovant Sciences Inc23$268
Astellas Pharma US Inc4$205
Convatec Inc.2$59
Vertex1$23
Axonics, Inc.1$23
180 Medical, Inc.1$19
Bluewind Medical1$17
Merck1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,610 in reported general payments places this provider in the 70th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$45,918
Medicare patients
200
Services billed
688

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron86$66,374
Estradiol40$2,327
Trospium Chloride53$2,323
Methenamine Hippurate19$2,032
ValacyclovirValacyclovir Hcl11$908
Desmopressin Acetate17$334
Doxycycline Monohydrate16$331
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav43$296
Cephalexin25$281
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst14$268
Nystatin11$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$331$66,37486 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →